Clinical Trials Browser

Phase 2 × alirocumab × 90 days × Clear all

NCT06385262 2026-03-06

TOP 2301: Neoadjuvant Chemo for NSCLC

Phase 2 Suspended

Carcinoma, Non-Small-Cell Lung

NCT05553834 2026-01-23

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung